Literature DB >> 9873091

Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis.

A L Doughty1, D M Painter, G W McCaughan.   

Abstract

Detection of hepatitis C virus (HCV) antigens in liver tissue provides important diagnostic and pathological information. Limited studies have been performed on tissue taken after liver transplantation for HCV. In this study, serial post-liver transplantation biopsy tissue from patients with recurrent HCV was tested, with particular interest in patients showing severe cholestatic hepatitis. HCV-related antigens were detected using the commercial monoclonal antibody, Tordji-22. Initial results were promising, showing intense positive staining, especially in areas of hepatocyte ballooning. HCV-negative donor tissue was consistently negative by staining. However, as a final control for the level of tissue damage, HCV negative posttransplantation biopsy tissue showing hepatocyte ballooning was examined. These tissues also showed positive staining. All attempts to eliminate this nonspecific interaction failed. In conclusion, Tordji-22 was associated with nonspecificity in this posttransplantation population, and care is warranted when using this monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873091     DOI: 10.1002/lt.500050104

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  2 in total

Review 1.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation.

Authors:  F Fenwick; M F Bassendine; K Agarwal; D Bevitt; W Pumeechockchai; A D Burt; G L Toms
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.